Skip to content

Study · Randomized controlled trial · n = 25 · 2007

10 results

Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.

Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB

American journal of medical genetics. Part A1 Mar 2007Cited by 97 (Europe PMC)

PMID17103437 (opens in a new tab)DOI10.1002/ajmg.a.31468 (opens in a new tab)PepBankPUB-17103437
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In young children with Prader-Willi syndrome, GH normalized length/height SDS compared with untreated subjects (P < 0.005).

    In plain wordsIn young children with Prader-Willi syndrome, GH normalized height scores compared with untreated children.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLength/height SDS normalization
    Study

    n = 25

    Comparator
    Similarly aged untreated PWS subjects
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    1 mg/m(2)/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GH-treated PWS subjects demonstrated normalization of length/height standard deviation scores (SDS), faster head growth, increased lean body mass accrual, and decreased percent body fat (P < 0.005 for all parameters), as well as improved language (P = 0.05) and cognitive (P = 0.02) quotient Z-scores…
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In young children with Prader-Willi syndrome, GH increased head growth compared with untreated subjects (P < 0.005).

    In plain wordsIn young children with Prader-Willi syndrome, GH increased head growth compared with untreated children.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHead growth
    Study

    n = 25

    Comparator
    Similarly aged untreated PWS subjects
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    1 mg/m(2)/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GH-treated PWS subjects demonstrated normalization of length/height standard deviation scores (SDS), faster head growth, increased lean body mass accrual, and decreased percent body fat (P < 0.005 for all parameters), as well as improved language (P = 0.05) and cognitive (P = 0.02) quotient Z-scores…
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In young children with Prader-Willi syndrome, GH increased lean body mass accrual compared with untreated subjects (P < 0.005).

    In plain wordsIn young children with Prader-Willi syndrome, GH increased lean body mass growth compared with untreated children.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean body mass accrual
    Study

    n = 25

    Comparator
    Similarly aged untreated PWS subjects
    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    1 mg/m(2)/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GH-treated PWS subjects demonstrated normalization of length/height standard deviation scores (SDS), faster head growth, increased lean body mass accrual, and decreased percent body fat (P < 0.005 for all parameters), as well as improved language (P = 0.05) and cognitive (P = 0.02) quotient Z-scores…
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In young children with Prader-Willi syndrome, GH decreased percent body fat compared with untreated subjects (P < 0.005).

    In plain wordsIn young children with Prader-Willi syndrome, GH reduced body fat percentage compared with untreated children.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreasePercent body fat
    Study

    n = 25

    Comparator
    Similarly aged untreated PWS subjects
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1 mg/m(2)/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GH-treated PWS subjects demonstrated normalization of length/height standard deviation scores (SDS), faster head growth, increased lean body mass accrual, and decreased percent body fat (P < 0.005 for all parameters), as well as improved language (P = 0.05) and cognitive (P = 0.02) quotient Z-scores…
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In young children with Prader-Willi syndrome, GH improved language quotient Z-scores compared with untreated subjects (P = 0.05).

    In plain wordsIn young children with Prader-Willi syndrome, GH improved language scores compared with untreated children.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLanguage quotient Z-score
    Study

    n = 25

    Comparator
    Similarly aged untreated PWS subjects
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 mg/m(2)/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GH-treated PWS subjects demonstrated normalization of length/height standard deviation scores (SDS), faster head growth, increased lean body mass accrual, and decreased percent body fat (P < 0.005 for all parameters), as well as improved language (P = 0.05) and cognitive (P = 0.02) quotient Z-scores…
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In young children with Prader-Willi syndrome, GH improved cognitive quotient Z-scores compared with untreated subjects (P = 0.02).

    In plain wordsIn young children with Prader-Willi syndrome, GH improved cognitive scores compared with untreated children.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCognitive quotient Z-score
    Study

    n = 25

    Comparator
    Similarly aged untreated PWS subjects
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 mg/m(2)/day · 1 yearAs given in this study (human).

    Source sentences

    Summary
    GH-treated PWS subjects demonstrated normalization of length/height standard deviation scores (SDS), faster head growth, increased lean body mass accrual, and decreased percent body fat (P < 0.005 for all parameters), as well as improved language (P = 0.05) and cognitive (P = 0.02) quotient Z-scores…
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  7. 07HumanNon-randomized trialEfficacy outcome

    Children with Prader-Willi syndrome treated with GH before their first birthday spoke their first words at 14.4 ± 2.8 months.

    In plain wordsChildren with Prader-Willi syndrome treated with GH before their first birthday spoke their first words at a mean 14.4 months.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableAge at first words
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 mg/m(2)/dayAs given in this study (human).

    Measurements

    Age at first words
    14.4 months
    mean

    Source sentences

    Summary
    PWS subjects treated before their first birthday spoke their first words at a mean age of 14.4 +/- 2.8 months and walked independently at 23.3 +/- 4.8 months.
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  8. 08HumanNon-randomized trialEfficacy outcome

    Children with Prader-Willi syndrome treated with GH before their first birthday walked independently at 23.3 ± 4.8 months.

    In plain wordsChildren with Prader-Willi syndrome treated with GH before their first birthday walked independently at a mean 23.3 months.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableAge at independent walking
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    1 mg/m(2)/dayAs given in this study (human).

    Measurements

    Age at independent walking
    23.3 months
    mean

    Source sentences

    Summary
    PWS subjects treated before their first birthday spoke their first words at a mean age of 14.4 +/- 2.8 months and walked independently at 23.3 +/- 4.8 months.
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  9. 09HumanNon-randomized trialSafety outcome

    In young children with Prader-Willi syndrome, GH therapy was well tolerated, but one child had scoliosis progression.

    In plain wordsIn young children with Prader-Willi syndrome, GH therapy was well tolerated, but one child had scoliosis progression.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableTreatment tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH therapy was well-tolerated; however, one PWS subject experienced scoliosis progression.
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.
  10. 10HumanNon-randomized trialSafety outcome

    One child with Prader-Willi syndrome experienced scoliosis progression during the GH study.

    In plain wordsOne child with Prader-Willi syndrome experienced worsening scoliosis during the GH study.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableScoliosis progression
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH therapy was well-tolerated; however, one PWS subject experienced scoliosis progression.
    1 context sentence
    Summary · context
    Twenty-five subjects, ages 4-37 months, were randomized to 2 years of GH therapy (1 mg/m(2)/day) or 1 year of observation without GH treatment and then placed on GH (1.5 mg/m(2).day) for 1 year only.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.